Review



primaquine sr  (Ipca Laboratories)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Ipca Laboratories primaquine sr
    Disposition of study participants. PT: <t>primaquine</t> therapy, CT: chloroquine therapy, and MP: malarial parasite.
    Primaquine Sr, supplied by Ipca Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primaquine sr/product/Ipca Laboratories
    Average 90 stars, based on 1 article reviews
    primaquine sr - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study"

    Article Title: Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study

    Journal: Malaria Research and Treatment

    doi: 10.1155/2015/579864

    Disposition of study participants. PT: primaquine therapy, CT: chloroquine therapy, and MP: malarial parasite.
    Figure Legend Snippet: Disposition of study participants. PT: primaquine therapy, CT: chloroquine therapy, and MP: malarial parasite.

    Techniques Used:

    Kaplan-Meier estimates of cumulative risk of relapse. P 15 mg: conventional primaquine 15 mg, PSR 15 mg: primaquine sustained release 15 mg, and PSR 30 mg: primaquine sustained release 30 mg. Numbers written over the line are patients still undergoing follow-up. Differences in cumulative risk of relapse are statistically insignificant; p = 0.16 for test of equality over strata using Log rank test.
    Figure Legend Snippet: Kaplan-Meier estimates of cumulative risk of relapse. P 15 mg: conventional primaquine 15 mg, PSR 15 mg: primaquine sustained release 15 mg, and PSR 30 mg: primaquine sustained release 30 mg. Numbers written over the line are patients still undergoing follow-up. Differences in cumulative risk of relapse are statistically insignificant; p = 0.16 for test of equality over strata using Log rank test.

    Techniques Used:

    Numbers of AEs reported during chloroquine therapy and primaquine therapy.
    Figure Legend Snippet: Numbers of AEs reported during chloroquine therapy and primaquine therapy.

    Techniques Used:



    Similar Products

    primaquine sr  (Ipca Laboratories)
    90
    Ipca Laboratories primaquine sr
    Disposition of study participants. PT: <t>primaquine</t> therapy, CT: chloroquine therapy, and MP: malarial parasite.
    Primaquine Sr, supplied by Ipca Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primaquine sr/product/Ipca Laboratories
    Average 90 stars, based on 1 article reviews
    primaquine sr - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Disposition of study participants. PT: primaquine therapy, CT: chloroquine therapy, and MP: malarial parasite.

    Journal: Malaria Research and Treatment

    Article Title: Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study

    doi: 10.1155/2015/579864

    Figure Lengend Snippet: Disposition of study participants. PT: primaquine therapy, CT: chloroquine therapy, and MP: malarial parasite.

    Article Snippet: The concept of developing primaquine SR 15 mg (manufactured by Ipca Labortories Ltd., India) and primaquine SR 30 mg (manufactured by Ipca Labortories Ltd., India) formulations was based on maintaining adequate therapeutic concentration over 24 hours and reducing the treatment duration from 14 days to seven days for better patient compliance.

    Techniques:

    Kaplan-Meier estimates of cumulative risk of relapse. P 15 mg: conventional primaquine 15 mg, PSR 15 mg: primaquine sustained release 15 mg, and PSR 30 mg: primaquine sustained release 30 mg. Numbers written over the line are patients still undergoing follow-up. Differences in cumulative risk of relapse are statistically insignificant; p = 0.16 for test of equality over strata using Log rank test.

    Journal: Malaria Research and Treatment

    Article Title: Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study

    doi: 10.1155/2015/579864

    Figure Lengend Snippet: Kaplan-Meier estimates of cumulative risk of relapse. P 15 mg: conventional primaquine 15 mg, PSR 15 mg: primaquine sustained release 15 mg, and PSR 30 mg: primaquine sustained release 30 mg. Numbers written over the line are patients still undergoing follow-up. Differences in cumulative risk of relapse are statistically insignificant; p = 0.16 for test of equality over strata using Log rank test.

    Article Snippet: The concept of developing primaquine SR 15 mg (manufactured by Ipca Labortories Ltd., India) and primaquine SR 30 mg (manufactured by Ipca Labortories Ltd., India) formulations was based on maintaining adequate therapeutic concentration over 24 hours and reducing the treatment duration from 14 days to seven days for better patient compliance.

    Techniques:

    Numbers of AEs reported during chloroquine therapy and primaquine therapy.

    Journal: Malaria Research and Treatment

    Article Title: Sustained Release Formulation of Primaquine for Prevention of Relapse of Plasmodium vivax Malaria: A Randomized, Double-Blind, Comparative, Multicentric Study

    doi: 10.1155/2015/579864

    Figure Lengend Snippet: Numbers of AEs reported during chloroquine therapy and primaquine therapy.

    Article Snippet: The concept of developing primaquine SR 15 mg (manufactured by Ipca Labortories Ltd., India) and primaquine SR 30 mg (manufactured by Ipca Labortories Ltd., India) formulations was based on maintaining adequate therapeutic concentration over 24 hours and reducing the treatment duration from 14 days to seven days for better patient compliance.

    Techniques: